Kezar Life Sciences Inc

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Kezar is a founder-driven company with deep expertise in proteasome and drug development, and they have a track record of approved medicines. The company's lead asset, KZR-616, is a first-in-class inhibitor of the immunoproteasome with the potential to become a pipeline-in-a-pill for autoimmunity.

Kezar Life Sciences: Targeting The Immunoproteasome To Treat Autoimmunity

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference, being held on January 11-14, 2021. The presentation will be available on Monday, January 11, 2021 at 6:00am EST and may be accessed

Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®

Kezar Life Sciences Added to the Nasdaq Biotechnology Index

SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will present during upcoming virtual investor conferences. The details of the presentations are as follows: Jefferies Virtual London Healthcare Conference Wednesday, November 18, 2020, 1:10pm EST (Fireside Chat) Presenters: John Fowler, Ch

Kezar Life Sciences to Present During Upcoming Virtual Investor Conferences

Kezar is a young company with two candidates in clinical development. Development programs with broad therapeutic potential.

Kezar Life Sciences: Keyed In On Autoimmune Therapies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its third-quarter 2020 financial results and corporate highlights. “The third quarter of 2020 saw continued momentum for Kezar, punctuated by the U.S. FDA granting Orphan Drug Designations for our lead candidate KZR-616 for the treatment of polymyositis and der

Kezar Life Sciences Reports Third-Quarter 2020 Financial Results and Provides Business Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today highlighted the broad therapeutic potential of KZR-616, a first-in-class immunoproteasome inhibitor, in two poster sessions during the American College of Rheumatology Annual Meeting (ACR Convergence 2020). Both posters can be found on Kezar's website under the “Science”

Kezar Highlights Broad Therapeutic Potential of KZR-616 During ACR Convergence 2020

SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designations (ODD) for KZR-616 for the treatment of polymyositis (PM) and dermatomyositis (DM). Both orphan diseases are autoimmune inflammatory myopathies that are chronic and debilitating diseases character

Kezar Life Sciences Announces Orphan Drug Designations for KZR-616 for the Treatment of Polymyositis and Dermatomyositis

SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced six presentations during four upcoming medical and scientific conferences. “The growing body of data around KZR-616, our first-in-class selective immunoproteasome inhibitor, support its unique and powerful immunomodulatory mechanism to tackle severe immune-mediated diseases

Kezar Life Sciences to Present at Four Upcoming Virtual Medical and Scientific Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc.

Kezar Highlights Data from MISSION Phase 1b Study of KZR-616 during the Pan American Congress of Rheumatology

Kezar Life Sciences to Present at The Myositis Association International Annual Patient Conference and the Pan-American Congress of Rheumatology

Kezar Life Sciences: Exploring New Options For Autoimmune Diseases

Kezar Life Sciences to Participate in Upcoming Virtual Investor Conferences

Kezar Life Sciences, Inc. (KZR) CEO John Fowler on Q2 2020 Results - Earnings Call Transcript

SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its second quarter 2020 financial results and corporate highlights.

Kezar Life Sciences Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update

Kezar Life Sciences to Participate in Two Upcoming Virtual Investor Conferences

Kezar Life Sciences to Release Second Quarter Financial Results and General Business Updates on August 5, 2020

The company's public offering of common stock doesn't exactly thrill investors.

Why Kezar Life Sciences Is Down Today

Kezar Life Sciences just released interim results on its only drug and shares jumped 70%. Now that the stock has settled, is it a good time to buy?

Is This Flaming Hot Biotech Stock a Buy?

SOUTH SAN FRANCISCO, Calif., June  08, 2020  (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced the pricing of an underwritten public offering of 7,590,909 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 909,091 shares of its common stock at an exercise price of $0.001 per share. The public offering price of each share of common stock is $5.50 and the public offering price of each pre-funded warrant is $5.499 per underlying share. In addition, Kezar has granted the underwriters a 30-day option to purchase up to an additional 1,275,000 shares of common stock. The offering is expected to close on June 11, 2020, subject to customary closing conditions.

Kezar Announces Pricing of a Public Offering of $46.7 million of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., June  08, 2020  (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the common stock in the offering will be sold by Kezar. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Kezar Announces Proposed Public Offering of Common Stock

AbbVie

Aldeyra Therapeutics

Aldeyra's Reproxalap Progress And Other News: The Good, Bad And Ugly Of Biopharma

SOUTH SAN FRANCISCO, Calif., June  03, 2020  (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced updated results from the Phase 1b (Ph1b) portion of MISSION, which is evaluating the safety and tolerability of KZR-616 in patients with systemic lupus erythematosus (SLE) with and without nephritis.

Kezar Provides Data Update from MISSION Study of KZR-616

Kezar Life Sciences (KZR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

News for Kezar Life Sciences Inc Stock (KZR)